Blueprint Medicines Corp expected to post a loss of $2.65 a share - Earnings Preview

Blueprint Medicines

14/02/2023 13:34

* Blueprint Medicines Corp  BPMC.OQ   BPMC.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
16. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 67.8% decrease in revenue to $34.435 million from $107.02
million a year ago, according to the mean estimate from 16
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Blueprint Medicines
Corp
is for a loss of $2.65 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $75​, above​ its last closing price of $43.97.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -2.46       -2.49      -2.23     Beat    10.3
 Jun. 30 2022  -2.25       -2.23      -2.68     Missed  -20.3
 Mar. 31 2022  -1.78       -1.86      -1.79     Beat    3.9​
 Dec. 31 2021  -2.48       -1.65      -5.40     Missed  -228.1
 ​​Sep.        -1.63       -1.63      -1.94     Missed  -19.1
 30 2021                                                
 Jun. 30 2021  -1.83       -1.86      -1.86     Met     0​
 Mar. 31 2021  -1.91       -1.87      -1.72     Beat    8
 Dec. 31 2020  -1.58       -1.62      -1.53     Beat    5.8
 This summary was machine generated February 14 at 13:34 GMT. 
All figures in US dollars  unless otherwise stated